Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | CLPP | Q16740 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | RHOC | P08134 | 1/20 | 0.40 |
| ▸ | RHOA | P61586 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315909 | 0.83 | CES2 (0.42) | AKR1C3AKR1C2MAPTCES2TACR1 | |
| SCHEMBL5226184 | 0.83 | AKR1C3 (0.46) | MAPK1AKR1C3AKR1C2NOTUMMAPT | |
| Hydrochloric Acid SCHEMBL4021440 | 0.81 | EPHX1 (0.44) | AKR1C3AKR1C2MAPTCES2TACR1 | |
| SCHEMBL7758695 | 0.81 | MAPK1 (0.51) | MAPK1AKR1C3AKR1C2NOTUMMAPT | |
| SCHEMBL4030295 | 0.81 | CES2 (0.44) | AKR1C3AKR1C2MAPTCES2TACR1 | |
| SCHEMBL5326225 | 0.79 | MAPK1 (0.43) | MAPK1AKR1C3AKR1C2NOTUMMAPT | |
| SCHEMBL1565616 | 0.78 | NOTUM (0.45) | MAPK1AKR1C3AKR1C2NOTUMMAPT | |
| SCHEMBL5765948 | 0.75 | CHRM2 (0.45) | MAPK1NOTUMMAPTCES2TACR1 | |
| SCHEMBL27643901 | 0.75 | SCN9A (0.44) | MAPK1AKR1C3AKR1C2SCN9ATACR1 | |
| SCHEMBL5768734 | 0.74 | CETP (0.42) | MAPK1NOTUMMAPTCES2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625904-B2 | Methods for the treatment of sleep disorders | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1460066-B1 | Piperazine compounds as Tachykinins inhibitors | GLAXO GROUP LTD (GB) | 2009-07-01 | — | — | EP | disclosed |
| US-20080249108-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | US | disclosed |
| EP-1454901-B1 | Pharmaceutical compositions comprising tachykinins antagonists and a serotonin reuptake inhibitor. | GLAXO GROUP LTD (GB) | 2008-09-03 | — | — | EP | disclosed |
| CN-100413850-C | Chemical compounds | GLAXO GROUP LTD (GB) | 2008-08-27 | — | — | CN | disclosed |
| US-7345041-B2 | treatment of sleep disorders or inflammatory diseases of the bladder by administering N-benzyl-2-phenylpiperazine-1-carboxamides, e.g., 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide methansulphonate | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-18 | — | — | US | disclosed |
| US-RE39921-E1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-13 | — | — | US | disclosed |
| US-7071196-B2 | Chemical compounds | SMITHKLINE BEECHAM CROPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060122192-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2006-06-08 | — | — | US | disclosed |
| US-6951861-B1 | Chemical compounds | SMITHKLINE BEECHAN CORPORATION (US) | 2005-10-04 | — | — | US | disclosed |
| US-20040209893-A1 | treatment of a condition mediated by a tachykinin including substance P and other neurokinins by administering N-benzyl-2-phenylpiperazine-1-carboxamides, e.g., 2-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic Acid (3,5-bistrifuoromethyl-benzyl)-methyl-amide Hydrochloride . | GLAXOSMITHKLINE LLC | 2004-10-21 | — | — | US | disclosed |
| EP-1460066-A1 | Piperazine compounds | GLAXO GROUP LIMITED (GB) | 2004-09-22 | — | — | EP | disclosed |
| EP-1454901-A1 | Piperazine compounds and pharmaceutical compositions containing them. | GLAXO GROUP LIMITED (GB) | 2004-09-08 | — | — | EP | disclosed |
| US-20040048862-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2004-03-11 | — | — | US | disclosed |
| US-6642240-B2 | Piperazine derivatives; antagonists of tachykinins, including substance P; 2-(4-fluoro-2-methyl-phenyl)piperazine-1-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)methyl amide for example | SMITHKLINE BEECHAM CORPORATION | 2003-11-04 | — | — | US | disclosed |
| US-20030028021-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2003-02-06 | — | — | US | disclosed |
| CN-1391564-A | Chemical compounds | GLAXO GROUP LTD (GB) | 2003-01-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030028021-A1 | Chemical compounds | TACR1, TACR2, TAC3 | MAPK1 1103/4885AKR1C3 2043/4885AKR1C2 2217/4885 |
| US-20060122192-A1 | Chemical compounds | TACR1, TACR2, TAC3 | MAPK1 1103/4885AKR1C3 2043/4885AKR1C2 2217/4885 |
| US-20040048862-A1 | Chemical compounds | TACR1, TACR2, TAC3 | MAPK1 1103/4885AKR1C3 2043/4885AKR1C2 2217/4885 |
| US-20040209893-A1 | treatment of a condition mediated by a tachykinin including substance P and other neurokinins by administering N-benzyl-2-phenylpiperazine-1-carboxamides, e.g., 2-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic Acid (3,5-bistrifuoromethyl-benzyl)-methyl-amide Hydrochloride . | TACR1, TACR2, NPSR1 | MAPK1 978/4885AKR1C3 2572/4885AKR1C2 2841/4885 |
| US-20080249108-A1 | Chemical Compounds | CYP11B2, CYP11B1, CYP21A2 | MAPK1 2563/4885AKR1C3 128/4885AKR1C2 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.